CVR: 39791447
Secondary names: Jazz Pharmaceuticals Nordics ApS
DKK 41,044,332
Gross profit
Net result: DKK 1,528,396
Jazz Pharmaceuticals Ireland Holdings Limited
CVR · view ownership and management
Director role ended: Samantha Jane Laura Pearce
CVR · 17/01/2025
View the full event history
Jazz Pharmaceuticals Denmark ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Kamilla Enggaard Have and David James Spackman. The company is owned by Jazz Pharmaceuticals Ireland Holdings Limited. In 2025, the company reported a gross profit of DKK 41,044,332 and a net result of DKK 1,528,396 compared with DKK 1,538,214 the year before. Equity in the 2025 report amounted to DKK 13,823,507.
Source: annual report 2025, Danish Business Authority
The financial health of Jazz Pharmaceuticals Denmark ApS appears stable, with a consistent increase in gross profit over the past five years, rising from 21.7 million DKK in 2021 to 41.0 million DKK in 2025. Profitability has fluctuated, peaking at 1.97 million DKK in 2022 before stabilizing around 1.5 million DKK in the following years. The company's equity has shown a positive trajectory, growing from 8.2 million DKK in 2021 to 13.8 million DKK in 2025, indicating a solid equity position. However, the absence of disclosed revenue figures raises concerns about overall sales performance, which may impact its competitive standing in the medicinal wholesale industry.
AI-generated summary · Generated 15/08/2026
Selskabets formål er at markedsføre, distribuere og sælge produkter og tjenesteydelser samt al virksomhed, som efter direktionens skøn har forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 41 mio. | 1.5 mio. | 45 mio. | 13.8 mio. | 19 | |
| 202401/01/2024 – 31/12/2024 | 36.7 mio. | 1.5 mio. | 32.5 mio. | 12.3 mio. | 18 | |
| 202301/01/2023 – 31/12/2023 | 31.8 mio. | 595 t. | 36.1 mio. | 10.8 mio. | 17 | |
| 202201/01/2022 – 31/12/2022 | 30.4 mio. | 2 mio. | 27.5 mio. | 10.2 mio. | 16 | |
| 202101/01/2021 – 31/12/2021 | 21.7 mio. | 560 t. | 21 mio. | 8.2 mio. | 10 | |
| 202001/01/2020 – 31/12/2020 | 16.5 mio. | 1.5 mio. | 19.3 mio. | 7.6 mio. | 14 |
Compared to 407 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
4 public tenders won
Sources: TED (the EU tender database) and udbud.dk
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreJazz Pharmaceuticals Denmark ApS was founded on 17 August 2018.
Jazz Pharmaceuticals Denmark ApS is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler (industry code 464610).
Jazz Pharmaceuticals Denmark ApS is owned by Jazz Pharmaceuticals Ireland Holdings Limited.
jazzpharma.com belongs to Jazz Pharmaceuticals Denmark ApS, CVR number 39791447.
In 2025, Jazz Pharmaceuticals Denmark ApS reported a gross profit of DKK 41,044,332.
The management of Jazz Pharmaceuticals Denmark ApS consists of Kamilla Enggaard Have and David James Spackman.
Claim this page to add your logo and social links. Free to get started.
Jazz Pharmaceuticals Denmark ApS has published its annual report for 2025. Gross profit came to DKK 41,044,332, and the net result was DKK 1,528,396.
Jazz Pharmaceuticals Denmark ApS has published its annual report for 2024. Gross profit came to DKK 36,708,802, and the net result was DKK 1,538,214.
As of January 17, 2025, David James Spackman is registered as director of Jazz Pharmaceuticals Denmark ApS.
As of January 17, 2025, Samantha Jane Laura Pearce has stepped down as director of Jazz Pharmaceuticals Denmark ApS.
Jazz Pharmaceuticals Denmark ApS has won the tender "Amgros 2025 1.711.b" issued by Amgros I/S worth 12,800,000 DKK.
Jazz Pharmaceuticals Denmark ApS has won the tender "Amgros 2025 1.1304.a" issued by Amgros I/S worth 83,949,231 DKK.
Jazz Pharmaceuticals Denmark ApS has won the tender "Amgros 2025 1.201.a" issued by Amgros I/S worth 149,993,922 DKK.
Jazz Pharmaceuticals Denmark ApS has published its annual report for 2023. Gross profit came to DKK 31,787,838, and the net result was DKK 595,176.
Jazz Pharmaceuticals Denmark ApS has won the tender "Amgros 2024 1.150.a" issued by Amgros I/S worth 73,756,763 DKK.
Jazz Pharmaceuticals Denmark ApS has published its annual report for 2022. Gross profit came to DKK 30,364,239, and the net result was DKK 1,972,936.
Jazz Pharmaceuticals Denmark ApS has published its annual report for 2021. Gross profit came to DKK 21,713,525, and the net result was DKK 560,263.
As of June 30, 2022, Kamilla Enggaard Have is registered as director of Jazz Pharmaceuticals Denmark ApS.
As of December 20, 2021, is registered as an owner of Jazz Pharmaceuticals Denmark ApS with an ownership share of 100%.
Jazz Pharmaceuticals Denmark ApS has published its annual report for 2020. Gross profit came to DKK 16,469,482, and the net result was DKK 1,540,505.
As of May 21, 2021, KPMG P/S has been appointed auditor of Jazz Pharmaceuticals Denmark ApS.
As of April 22, 2021, Samantha Jane Laura Pearce is registered as director of Jazz Pharmaceuticals Denmark ApS.
As of April 22, 2021, Joseph Dagher has stepped down as director of Jazz Pharmaceuticals Denmark ApS.
Jazz Pharmaceuticals Denmark ApS has published its interim report for the period August 17, 2018 – December 31, 2019.
As of August 17, 2018, Joseph Dagher is registered as director of Jazz Pharmaceuticals Denmark ApS.
Jazz Pharmaceuticals Denmark ApS was founded on August 17, 2018.
Companies in the same industry and area
CVR 37626619
CVR 44476533
CVR 33860463
CVR 35234748
CVR 39762560
